While their prevalence in the United States (US) may be relatively low, ‘rare’ diseases have been garnering increasing attention in recent years through such channels …

From discovery to clinical trials, to marketing and managing medicinal products on the market, artificial intelligence (AI) is delivering promise and possibility to the life …

The US Food and Drug Administration (FDA) has approved eight biosimilars since May 2018 – seven in 2018 and one more in January 2019 – …

With the rapid transformation and the global growth of clinical trials, controlling the cost and achieving more effective investment of the resources that small startups …

Clinical trial insurance is intended to compensate patientvolunteers (“volunteers”) in a clinical trial (or their dependents) for death or injury arising out of their participation …

The push by pharma companies to develop more targeted compounds in response to unmet medical needs, and the large return on investment these successful therapies …

The global pharmaceutical industry has entered an exciting new era of drug development, bringing new hope to patients around the world. It is estimated that …

Any issues in the recruitment and retention of subjects for a clinical trial can result in delays and unnecessary costs, and may even potentially undermine …

Although Duchenne Muscular Dystrophy (DMD) is a rare disease, multiple targets are being pursued to find treatments. As a result, DMD patients have several options …

Patients with diabetes have an up to 50% increased risk of cardiovascular (CV) disease (CVD) compared to individuals without diabetes. Optimisation of glycaemic control can …